OvaScience OVAS
Seite 4 von 6 Neuester Beitrag: 25.04.21 01:17 | ||||
Eröffnet am: | 23.06.17 18:19 | von: wallander | Anzahl Beiträge: | 141 |
Neuester Beitrag: | 25.04.21 01:17 | von: Antjejsbea | Leser gesamt: | 28.107 |
Forum: | Hot-Stocks | Leser heute: | 31 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | | 5 | 6 > |
Moderation
Zeitpunkt: 14.04.18 07:55
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Handlungsempfehlung
Zeitpunkt: 14.04.18 07:55
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Handlungsempfehlung
Moderation
Zeitpunkt: 14.04.18 07:55
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - unbelegte Aussage.
Zeitpunkt: 14.04.18 07:55
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - unbelegte Aussage.
sa fällt mir nix mehr zu ein :-))))))
wo haben SIe dich denn ausgegraben, hoffe du hast für deine Behauptungen auch ein paar Links dazu die das bestätigen !!!
https://www.sec.gov/Archives/edgar/data/1544227/.../a18-12707_18k.htm
steht wohl ein Merger an, Ladenburg Thalmann wurde beauftragt, Mergerspezialsiten ;-)
was dafür spricht, dass die weiter runterfahren die Crew nochmal um 20%, vorher waren es 50% und jetzt ca. 70% insgesamt...
In connection with the restructuring plan, the Company plans to reduce its workforce by approximately 70%, with the majority of the reduction in personnel expected to be completed by June 30, 2018
https://fintel.io/doc/www.sec.gov/Archives/edgar/...a18-12707_18k.htm
könnte sich jetzt noch schneller zum Net Cash hinbewegen, der ca. bei 1,40$ liegen dürfte
auf gehts
OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update
WALTHAM, Mass.--(BUSINESS WIRE)--May 3, 2018-- OvaScienceSM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
OvaScience is completing preclinical studies designed to evaluate its egg precursor (EggPCSM) cell technology platform and inform the future development of OvaPrime. Based on preliminary data from these experiments and those of OvaScience’s academic collaborators, the Company has decided to scale back investments in its OvaPrime research and development efforts, including halting its planned Phase 1b/2a clinical trial. The Company has done so in order to preserve resources while it completes these experiments and awaits the final results, and while it continues to monitor patients in its ongoing Phase 1 clinical trial. Under the leadership of Dr. James Lillie, Chief Scientific Officer, a small internal scientific team will continue in-house efforts to progress the Company’s OvaTure program in conjunction with specialized contract research organizations and select academic partners. The Company will also continue to offer AUGMENT to patients in Japan through an exclusive license to IVF Japan Group.
Additionally, OvaScience’s management team and Board of Directors have initiated a process to explore a range of strategic alternatives for enhancing shareholder value, including the potential sale or merger of the Company. The Board has established a Business Development Committee that will work with management to oversee this process. Ladenburg Thalmann & Co. Inc. has been engaged to act as OvaScience’s strategic financial advisor. There can be no assurance that this process will result in any such transaction and the Company does not intend to disclose additional details unless and until it has entered into a specific transaction.
In conjunction with these decisions, OvaScience will restructure its organization to streamline operations and reduce its cost structure, including reducing its workforce by approximately 70 percent. The majority of the reduction in personnel is expected to be completed by June 30, 2018. The Company expects to realize annualized cost savings beginning in the fourth quarter of 2018. OvaScience estimates that it will incur one-time costs of approximately $0.5 million to $1.0 million related to the restructuring plan.
“We continue to seek value by deepening our understanding of EggPC cells,” said Dr. Christopher Kroeger, Chief Executive Officer of OvaScience. “We are further exploring the potential of our technology platform, as we streamline our organization to conserve capital and engage in a careful review of external opportunities with the goal of maximizing shareholder value.”
First Quarter 2018 Financial Results:
Research and development expenses for the quarter ended March 31, 2018, excluding restructuring costs, were $2.6 million, compared to $5.8 million for the same period in 2017. This decrease was primarily driven by decreased headcount and employee related costs, including stock-based compensation expense.
Selling, general and administrative expenses for the quarter ended March 31, 2018, excluding restructuring costs, were $4.2 million, compared to $7.1 million for the same period in 2017. This decrease was primarily driven by decreased headcount and employee related costs, including stock-based compensation expense.
Net loss for the quarter ended March 31, 2018 was $7.4 million, or $0.21 per share, compared to a net loss of $14.9 million, or $0.42 per share, for the same period in 2017. The net loss for the quarter ended March 31, 2018 includes restructuring charges of $0.7 million, compared to $1.5 million for the same period in 2017.
As of March 31, 2018, OvaScience had cash, cash equivalents and short-term investments of $58.3 million, compared to $67.2 million as of December 31, 2017.
Gross cash burn in the first quarter of 2018 was $8.9 million. This includes other reductions in working capital of $2.0 million as the Company realizes the impact of its prior restructuring activities. The cash outlays related to the restructurings in the first quarter of 2018 were $0.6 million. OvaScience expects to incur additional cash outlays related to the restructurings of between $1.0 million and $1.5 million over 2018.
About OvaScience
OvaScience, Inc. (Nasdaq:OVAS) is a company focused on the development of new treatment options for women and couples struggling with infertility. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of EggPC cells – immature egg cells found within the outer ovarian cortex. OvaPrime is a potential fertility treatment that could help restore a woman’s egg production, and OvaTure is a potential fertility treatment that eliminates the need for hormone stimulation. OvaScience’s AUGMENT treatment, designed to improve embryo development and pregnancy rates, is available in Japan under an exclusive license to IVF Japan. OvaScience treatments are not available in the United States. For more information, visit www.ovascience.com.
Klar, man hätte auch sofort auf einen Merger spekulieren können...aber nennen wir es mal sowas wie "Restsicherheit".
Jetzt kann die Fantasie kommen...wieviel da dran ist werden wir sehen oder man kassiert auf dem Weg dahin ab. Wie`s beliebt...war bei Biodel und Neothetics ja ähnlich , bevor gemerged wurde.
Etwas müssen wir uns noch gedulden, zumindest wenn es wie immer abläuft. Die Erfahrung zeigt, dass es nach Ankündigung von –neuen strategischen Optionen– ca. 3 Monate dauert bis die Merger–Nachricht verkündet wird. Für OVAS bedeutet es, dass die Zeit ab 04.05.18 läuft. Also sollten wir Anfang/Mitte August die Nachricht über einen Merger bekommen. So lief es bspw. bei Nivalis (jetzt Alpine), Biodel (jetzt Albireo) oder auch Mast Therapeutics (jetzt Savara).
Sollte man sich Gedanken machen, dass es eventuell länger dauert, dann wäre nur Oktober als nächster Termin zu nennen. Dort könnte ein Delisting der Nasdaq drohen. D.h. bis Oktober sollte der Kurs 10 Tage über USD 1 liegen, dann wäre das auch vom Tisch. Da wir eh um die 1 USD kreisen, sollte das kein Thema werden zumal man die Frist auf Antrag 1x verlängern kann.
So bleibt zuletzt der Buchwert. Da wir im Buchwert bei ca USD 1,60 im Mai standen und OVAS zu Juni/Juli dem Großteil des Personals gekündigt hat, dürfte die Cash Burn–Rate sich deutlich reduzieren. Selbst wenn wir in 3–6 Monaten noch bei einem Buchwert von USD 1,40 ( hab es jetzt nicht ausgerechnet) dann ist der Wert immer noch über dem jetzigen Kurs und die Merger–Botschaft ist noch nicht eingepreist.
Fazit: In die Sommerferien fahren, abwarten und das Urlaubsgeld im August über einen schönen Kursanstieg wieder reinholen.
~Stay Long Taradis